Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue 6, 2002, Pages 371-391

  Bayes M ^a   Rabasseda, X ^a   Prous, J R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALEMTUZUMAB; ALENDRONIC ACID; ALICAFORSEN; ALTEPLASE; AMIFOSTINE; ATORVASTATIN; AZATHIOPRINE; BCG VACCINE; BICALUTAMIDE; BIMATOPROST; BRIMONIDINE; BUPRENORPHINE; CABERGOLINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DESMOPRESSIN ACETATE; DIHYDROERGOTAMINE MESILATE; DORZOLAMIDE; DOXORUBICIN; DUTASTERIDE; EVEROLIMUS; FLUOCINOLONE ACETONIDE; FROVATRIPTAN; INTERLEUKIN 2 RECEPTOR ANTIBODY; THYMOCYTE ANTIBODY;

ARTICLE; BLADDER TUMOR; BREAST CARCINOMA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG DESIGN; DRUG FORMULATION; GLAUCOMA; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; INTRAOCULAR HYPERTENSION; MEDICAL RESEARCH; NOCTURIA; PAIN; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; PSORIASIS; RESTLESS LEGS SYNDROME; SCIENTIFIC LITERATURE; CONTROLLED CLINICAL TRIAL; DRUG THERAPY; RANDOMIZED CONTROLLED TRIAL;

DRUG THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036332557     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. A comparison of the efficacy and ocular comfort of ketotifen fumarate ophthalmic solution 0.025% and olopatadine hydrochloride 0.1% in the treatment of allergic conjunctivitis
2. Combined effect of omalizumab (rhuMAb-E25, Xolair®) and specific immunotherapy on nasal inflammation
3. Short-term effect of dorzolamide on central corneal thickness in humans with low endothelial cell count
4. Novel sustained drug delivery system in the management of diabetic macular edema
5. Intraocalar pressure lowering effect with substitution of bimatoprost for latanoprost
6. 1-Year comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension
7. Effectiveness of bimatoprost (Lumigan) as adjunctive therapy with topical beta-blockers in patients with glaucoma or ocular hypertension
8. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation following small incision cataract surgery
9. Effects of 0.03% bimatoprost on patients non-responders to 0.005% latanoprost: A cross-over study
10. Comparative effects of latanoprost and unoprostone on IOP, visual function, and POBF in open angle glaucoma
11. Travatan administration results in effective diurnal reduction in intraocular pressure over 36 hours and lower pressures up to 3.5 days without further dosing
12. Clinical experience with Timosan (timolol O.1% gel) in the treatment of different forms of glaucoma
13. Efficacy and safety of bimatroprost as additive and replacement therapy in patients uncontrolled with latanoprost: Early results
14. Effect of brimonidine on patients undergoing beta-blockers with I0P not controlled
15. Fluocinolone acetonide intravitreal implant to treat posterior uveitis
16. Topical immunosuppressive therapy in recurrence uveitis in children - Cyclosporin drops as excluding therapy
17. Long-term efficacy of mycophenolate mofetil in control of severe intraocular inflammation
18. Cost-effectiveness of Zelmac in the treatment of irritable bowel syndrome in Switzerland
19. Effectiveness safety of buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen in the treatment of patients with low back pain
20. The effects of controlled-release oxycodone on neuropathic pain sensations measured by the neuropathic pain scale
21. Topical lidocaine patch therapy for myofascial pain
22. Efficacy of topiramate in neuropathic pain: Retroaspective trial in 61 patients
23. Lidocaine patch 5% treats all neuropathic pain qualities: Results of a randomized clinical trial using the neuropathic pain scale
24. Initial experience with oxcarbazepine in the treatment of idiopathic neuropathic pain
25. An open-label trial of oxcarbazepine in patients with radiculopathy refractory to gabapentin
26. Analgesic efficacy and safety of buprenorphine transdermal system (BTDS) in patients with osteoarthritis
27. Long-term use of gabapentin for treatment of pain after traumatic spinal cord injury
28. The effect of amifostine on peripheral neuropathy after high dose paclitaxel
29. Aspirin for multiple sclerosis-related fatigue: Results of a double-blind placebo-controlled study
30. Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia
31. Oxcarbazepine versus carbamazepine in trigeminal neuralgia: A meta-analysis of three double-blind comparative trials
32. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
33. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
34. The effects of basiliximab induction therapy on rejection and hepatitis C recurrence in liver transplant recipients
35. The interaction between anti-retroviral agents and tacrolimus in liver and kidney transplant patients
36. Sequential proviral load measurements in three patients with HTLV-1 associated myelopathy treated with zidovudine
37. Atorvastatin decreases hepatic lipase activity in type 2 diabetes mellitus dose-dependently. Effect of gender and LIPC promoter variant
38. Combination therapy with raloxifene HCI and simvastatin is additive in reducing low density lipoprotein-cholesterol (LDL-C) in postmenopausal hypercholesterolemic women
39. Influence of bacillus Calmette-Guerin (BCG) therapy on the quality of life in patients with primary bladder cancer
40. Intravesical bacillus Calmette-Guerin treatment improves patient survival in conservatively treated T1G3 bladder tumours
41. Faslodex, a new pure antagonist for endocrine therapy of breast cancer
42. Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer
43. Phase II trial R115777 (Zanestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): A North American brain tumor consortium (NABTC) report
44. Humanized anti CD20 monoclonal antibody (rituximab) therapy for past transplant lymphoproliferative disorders in solid organ transplant recipients
45. A phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) sarasar (lonafarnib, SCH66336). cisplatin (C), and gemcitabine (G) in patients (pts) with advanced solid tumors
46. A phase I clinical, pharmacokinetic and pharmacodynamic study of the farnesyltransferase inhibitor BMS-214662 given as a 24 hour continous intravenous (IV) infusion once weekly x 3 in patients with advanced solid tumors
47. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662 in combination with paclitaxel and carboplatin in patients with advanced cancer
48. Phase I study of continuous oral lonafarnib plus weekly paclitaxel for advanced cancer
49. Phase I study of continuous lonafarnib plus paclitaxel and carboplatin in refractory or advanced solid tumors
50. A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) with paclitaxel in taxene-refractory/resistant patients with non-small cell lung cancer (NSCLC): Final report
51. Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC)
52. Farnesyl transferase inhibitor FTI-R11577 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathway in patients with advanced multiple myeloma
53. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC)
54. Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy
55. Clinical activity and inhibition of protein farnesylation in FTI-R115777 treated patients with myelodysplastic syndrome (MDS)
56. tPA for acute ischaemic stroke - The Singapore National University Hospital experience
57. A pilot study of the combination of caffeine plus ethanol (Caffeinol) in acute stroke
58. Prehospital ischemic stroke care in the tPA era
59. NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer's disease (AD)
60. Galantamine shows efficacy in treating cognitive decline in patients with probable vascular dementia
61. Galantamine demonstrates broad clinical efficacy over 12 months in patients with Alzheimer's disease with cerebrovascular disease and probable vascular dementia
62. The impact of L-dopa-induced dyskinesias on patients' quality of life in Parkinson's disease: A prospective European study
63. Safety and tolerability of oxcarbazepine in elderly patients
64. The use of DHE-45 for the treatment of intractable headache in children
65. Tizanidine HCL in the prophylaxis of chronic daily headache: Double-blind, placebo-controlled outcome study
66. Effectiveness of melatonin in the treatment of delayed sleep phase syndrome
67. Frovatriptan for the acute treatment of migraine: A dose-finding study
68. Quetiapine for migraine prophylaxis
69. Treatment of migraine with rizatriptan: When to take the medication
70. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized, double-blind, placebo-controlled study
71. Topiramate in migraine prophylaxis: An open-label extension of a double-blind, placebo-controlled study
72. Effect of glatiramer acetate treatment on multiple scleroris lesions with different degrees of ongoing inflammation
73. Beta interferon use among multiple sclerosis patients in a managed care setting: Demographics, cost of care, utilization, health status, and quality of life
74. A randomized study of low fat diet with omega-3 fatty acid supplimentation in patients with relapsing-remitting multiple sclerosis (RRMS)
75. The independent comparison of interferon (INCOMIN) trial: Final long-term results
76. Longitudinal magnetic resonance imaging study on the effect of azathioprine in relapsing-remitting multiple sclerosis patients refractory to the treatment with interferon beta-1b
77. Safety and efficacy of combination therapy with interferon beta-1b and mitoxantrone in worsening multiple slcerosis using monthly gadolinium enhanced MRI
78. Long term effect of intravenous (IV) cyclophosphamide (CTX) in rapidly pragressive MS patients
79. Evidence of an early dose effect of inteferon-beta 1a on relapse-free outcomes
80. Addition of a midday dose of modafinil sustains wakefulness in narcolepsy patients with residual evening sleepiness despite satisfactory daytime efficacy
81. Open treatment of Tourette Syndrome with metoclopramide: A case series
82. A multicenter trial of piribedil as early adjunct treatment of Parkinson's disease
83. Pramipexole versus levodopa: Effects on Parkinson disease progression assessed by dopamine transporter imaging
84. Pramipexole versus levodopa as initial treatment for Parkinson disease: A 4-year ramdomized controlled trial
85. The development of dyskinesias in Parkinson's disease (PD) patients receiving ropinirole and given supplemental L-dopa
86. The REAL-PET study: Slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa
87. Augmentation of restless legs syndrome after long-term treatment with pramipexole and cabergoline
88. Adjunctive open-label topiramate in bipolar disorder
89. Tolterodine extended release (ER): Safe, effective and well tolerated during long term treatment in overactive bladder patients
90. The effect of oral desmopressin (Minirin®) on sleep in male and female patients with nocturia
91. Prospective, randomised, placebo controlled trial of peri-prostatic local anaesthetic in trans-rectal prostate biopsy
92. The impact of dutasteride, a novel 5-alpha reductase inhibitor, on the hallmarks of BPH
93. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity
94. Omalizumab improves disease control in patients at high-risk of serious asthma-related morbidity and mortality
95. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
96. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
97. Pilot study of topical ISIS 2302, an antisense oligodeoxynucleotide, in patients with plaque type psoriasis vulgaris
98. Safety, tolerance, and disease activity of MEDI-507 (siplizumab) for the treatment of moderate to severe psoriasis
99. Defining a therapeutic range for everolimus in de novo heart transplantation based on exposure-response relationships
100. Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: Six-month analysis
101. 12-Month results of a multicenter study comparing efficacy and safety of everolimus to azathioprine in de novo cardiac transplant recipients
102. Everolimus (Certican™, RAD) reduces cardiac allograft vasculopathy
103. Oral bisphosphonate therapy for persisting osteopenia after liver transplantation
104. Pediatric evaluation of daclizumab as induction therapy following liver transplantation
105. Steroid-free regimen with daclizumab (Zx), mycophenolate mofetil (MMF), and tacrolimus (FK) in liver transplant recipients (6 months follow-up)
106. Long-term follow-up daclizumab induction in liver transplant recipients
107. Prevention of recurrent hepatitis B virus after liver transplantation with restricted elimination of hepatitis B immune globulin
108. CMV antigenemia directed preemptive therapy versus universal prophylaxis with ganciclovir in lung transplant recipients
109. Valganciclovir following combination prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin is effective for the prevention of CMV infections following lung transplantation
110. Two dose daclizumab regimen provides superior outcomes in simultaneous kidney-pancreas transplant recipients: Primary endpoint analysis of a multicenter, randomized study
111. Rapamycin and low-dose tacrolimus in kidney-pancreas recipients: A 12-36 month follow-up
112. Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function
113. Limited dose monoclonal IL-2R antibody induction in kidney transplantation - A prospective, randomized, controlled clinical trial
114. Alemtuzumab facilitates prednisonefree immunosuppression in kidney transplant recipients with no early rejection
115. Excellent renal tolerability of Neoral C-2h monitoring in de novo kidney transplantation: Initial results of the MO2ART trial
116. Monitoring of 2-hour Neoral absorption in renal transplantation (MO2ART): Interim analysis slows low incidence of acute rejection in the early post-graft period
117. Anti-CD25 prophylaxis allows steroid-free renal transplantation in tacrolimus-based immunosuppression
118. Exposure-response relaitonships for everolimus in de novo kidney transplantation: Defining a therapeutic range
119. Improved renal function following cyclosporine dose reduction in maintenance renal transplant recipients taking everolimus (Certican™)
120. Everolimus (Certican™, RAD) is associated with a reduced incidence of CMV infection following renal transplantation
121. Systemic exposure and preliminary efficacy of FTY720 in de novo renal transplant recipients
122. FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function
123. FTY720 induces lymphopenia but does not influence T-lymphocyte and monocyte function in renal transplant patients
124. Favorable lipid profile under FTY720 immunosuppression in renal transplant recipients
125. Pravastatin ameliorates hyper-cholesterolemia in pediatric renal transplant recipients
126. Steroid withdrawal in renal transplant patients immunosuppressed with tacrolimus
127. The effect of antibody induction in simultaneous pancreas kidney (SPK) transplant patients receiving tacrolimus (TAC) and mycophenolate mofetil (MMF): Two-year results
128. Conjunctival hyperemia with latanoprost, travoprost and bimatoprost
129. Effect of rosiglitazone on production rates of testosterone, dihydrotestosterone and of cortisol in healthy men